BioCrossroads

Lumavate is an enterprise platform for building progressive web apps (PWAs) at scale. Through the Lumavate platform, companies deliver highly-personalized mobile experiences throughout the entire customer journey. These mobile experiences drive increased adoption and long-term engagement via smart activation methods. Visit lumavate.com to learn more.

Kovina Therapeutics operates as a pre-clinical biotechnology company aims to discover a non-surgical, medical treatment for Human Papillomavirus (HPV) infections and cancers.

Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created a proprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.

MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics.

Sexton Biotechnologies announced today that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In addition to ongoing research and product development, Sexton Biotechnologies will expand and scale commercialization of its portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction.

Sabanto provides a Farming-as-a-Service tool to accelerate autonomy in agricultural machinery. Sabanto's core competency revolves around low-cost retrofits of existing agriculture machinery regardless of make or model, along with the development of supporting software to improve the utility of autonomous technology, thereby increasing producer ROI. Sabanto creates simple and cost-effective technologies that advance the future of agriculture.

Lumavate is an enterprise platform for building progressive web apps (PWAs) at scale. Through the Lumavate platform, companies deliver highly-personalized mobile experiences throughout the entire customer journey. These mobile experiences drive increased adoption and long-term engagement via smart activation methods. Visit lumavate.com to learn more.

OmniVis is a leading biotechnology company that has developed an integrated platform to transform the speed, accuracy, and economics of pathogen detection, anywhere in the world. OmniVis’ ultrasensitive handheld device provides a low-cost solution to labor intensive lab testing, bringing accurate results directly to the source in under 30 minutes.

Scioto Biosciences is a developer of Activated Bacterial Therapeutics (ABT) platform intended to deliver live bacteria to the gut. The company is developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics, enabling medical practitioners to advance healing through microbiome therapeutics.

Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases. The technology is based on the discovery by scientific founders Irina Petrache, MD, and Matthias Clauss, Ph.D. of a novel therapeutic target that plays a central role in the development and progression of lung disease.

SonarMed was founded in 2005 to commercialize technology licensed from Purdue University to improve the placement and monitoring of endotracheal (breathing) tubes (also known as ETTs or artificial airways) which are used in patients who cannot breathe on their own. The technology was initially developed at Purdue University by SonarMed founders Jeffrey Mans-field, Eduardo Juan and George Wodicka, using the principles of acoustic reflectometry in tubes to provide the medical community with a more comprehensive approach to assist in the maintenance of breathing tubes.

Scioto Biosciences is a developer of Activated Bacterial Therapeutics (ABT) platform intended to deliver live bacteria to the gut. The company is developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics, enabling medical practitioners to advance healing through microbiome therapeutics.

SpeechVive is a medical technology company that specializes in providing a communication solution for people with Parkinson's Disease. It also specializes in the fields of healthcare, medical, and medical device manufacturing. The company was founded in 2011 and is headquartered in Lafayette, Indiana.

Calibrium is an emerging privately-held biopharmaceutical company focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, Calibrium’s Chief Executive Officer, and Richard DiMarchi, PhD, Calibirum’s Chief Scientific Officer.

Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV). CpAMs can alter the activities of the HBV core protein, a unique viral protein with no human analogue that is involved in multiple stages of the HBV life cycle. In contrast to current therapies that only suppress HBV, Assembly Pharmaceutical’s CpAMs may have curative potential by eliminating the viral reservoir in infected individuals. Hepatitis B infection has a worldwide prevalence of over 350 million and more than 600,000 people die every year from complications associated with chronic HBV. Assembly has operations in Indiana and San Francisco.

Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided a unique insight into this novel biological target. It was founded in 2005 and headquartered in Indianapolis, Indiana.

Diagnotes builds mobile and web-based applications that reflect the natural communication habits of healthcare professionals and their patients. The enterprise-grade clinical communication and collaboration platform is fast to implement and highly intuitive to adopt. Diagnotes’ clients include large health systems, specialty and community hospitals, long-term care facilities, employers, and behavioral health organizations. Uses of the platform range from simple secure messaging to telehealth consults between specialists and their patients in rural areas using live video. Diagnotes help healthcare professionals communicate with each other, as well as with patients and caregivers, on a single, unified, cloud-based platform. Diagnotes was established in 2010 and is headquartered in Indianapolis, Indiana, United States.

SonarMed was founded in 2005 to commercialize technology licensed from Purdue University to improve the placement and monitoring of endotracheal (breathing) tubes (also known as ETTs or artificial airways) which are used in patients who cannot breathe on their own. The technology was initially developed at Purdue University by SonarMed founders Jeffrey Mans-field, Eduardo Juan and George Wodicka, using the principles of acoustic reflectometry in tubes to provide the medical community with a more comprehensive approach to assist in the maintenance of breathing tubes.

Bioscience Vaccines is a life-science company with proprietary adjuvant technology referred to as Matrix Immune Modulator and is based in the Purdue Research Park in West Lafayette, Ind. The company's products originated in the laboratory of Dr. Mark Suckow of the University of Notre Dame and are based on a technology discovered at Purdue University. The company's technology has the potential to be formulated as a companion product with vaccine products already approved and marketed for use by the FDA for the prevention of specific human and animal diseases.

ImmuneWorks develops immune tolerance treatments for patients with serious autoimmune diseases in the lung. The company was founded in 2006 to develop safe and effective immune tolerance treatments for patients with serious autoimmune diseases of the lung. The scientific foundation of the company is ImmuneWorks' groundbreaking discovery that antigen-specific autoimmunity is responsible for the disease in over one-half of idiopathic pulmonary fibrosis (IPF) patients. It was incorporated in 2006 and is based in Indianapolis, Indiana.

FlowCo is a medical device company developing products to improve the flow of blood through the vascular system.

CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.